Compare Stocks: GRCL, IRON, IMNM, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$26.75 +0.9%	$30.26	$15.60 ▼ $38.26	$2.76B	2.23	1.76 million shs	1.23 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
IMNM Immunome	$27.20 +3.0%	$22.20	$8.66 ▼ $28.62	$3.09B	2.08	974,126 shs	759,857 shs
IRON Disc Medicine	$78.84 -1.5%	$74.60	$40.00 ▼ $99.50	$302.32M	1	326,915 shs	262,542 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-2.66%	-5.78%	-4.22%	+52.68%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
IMNM Immunome	0.00%	+8.67%	+22.52%	+30.27%	+171.73%
IRON Disc Medicine	0.00%	+1.81%	+7.31%	+17.92%	+29.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$26.75 +0.9%	$30.26	$15.60 ▼ $38.26	$2.76B	2.23	1.76 million shs	1.23 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
IMNM Immunome	$27.20 +3.0%	$22.20	$8.66 ▼ $28.62	$3.09B	2.08	974,126 shs	759,857 shs
IRON Disc Medicine	$78.84 -1.5%	$74.60	$40.00 ▼ $99.50	$302.32M	1	326,915 shs	262,542 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-2.66%	-5.78%	-4.22%	+52.68%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
IMNM Immunome	0.00%	+8.67%	+22.52%	+30.27%	+171.73%
IRON Disc Medicine	0.00%	+1.81%	+7.31%	+17.92%	+29.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	83.18% Upside
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
IMNM Immunome	2.85	Moderate Buy	$34.64	27.34% Upside
IRON Disc Medicine	2.75	Moderate Buy	$106.00	34.45% Upside

Current Analyst Ratings Breakdown

Latest GRCL, IRON, IMNM, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$118.00 ➝ $120.00
7/21/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IMNM Immunome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IRON Disc Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	IMNM Immunome	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/8/2026	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$47.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	19.77	N/A	N/A	$10.34 per share	2.59
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
IMNM Immunome	$6.94M	445.16	N/A	N/A	$4.62 per share	5.89
IRON Disc Medicine	N/A	N/A	N/A	N/A	$167.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	N/A
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	N/A

Latest GRCL, IRON, IMNM, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.36%	N/A	N/A	N/A
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
GRCL Gracell Biotechnologies	0.02	7.73	7.73
IMNM Immunome	N/A	15.08	21.68
IRON Disc Medicine	0.09	24.14	24.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
GRCL Gracell Biotechnologies	N/A
IMNM Immunome	44.58%
IRON Disc Medicine	83.70%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
GRCL Gracell Biotechnologies	28.00%
IMNM Immunome	7.21%
IRON Disc Medicine	3.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	No Data
IMNM Immunome	40	113.58 million	105.39 million	Optionable
IRON Disc Medicine	30	3.84 million	3.69 million	Not Optionable

GRCL, IRON, IMNM, and BEAM Headlines

Recent News About These Companies

Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 804 Shares of Stock

August 15 at 7:36 AM | insidertrades.com

Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells 804 Shares

August 14 at 9:06 PM | marketbeat.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

August 14 at 11:17 AM | globenewswire.com

Sei Investments Co. Takes Position in Disc Medicine, Inc. $IRON

August 13 at 4:33 AM | marketbeat.com

Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil's Iron Quadrangle

August 12, 2026 | accessnewswire.comA

Renaissance Technologies LLC Sells 31,000 Shares of Disc Medicine, Inc. $IRON

August 11, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Decreases Stock Position in Disc Medicine, Inc. $IRON

August 10, 2026 | marketbeat.com

Disc Medicine (NASDAQ:IRON) Insider Sells $400,000.00 in Stock

August 10, 2026 | americanbankingnews.com

Disc Medicine, Inc. $IRON Shares Sold by Assenagon Asset Management S.A.

August 10, 2026 | marketbeat.com

HC Wainwright Decreases Earnings Estimates for Disc Medicine

August 10, 2026 | marketbeat.com

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON

August 9, 2026 | newsfilecorp.comN

Disc Medicine (NASDAQ:IRON) Price Target Raised to $120.00

August 9, 2026 | americanbankingnews.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

August 8, 2026 | markets.businessinsider.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

August 8, 2026 | newsfilecorp.comN

Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells $400,000.00 in Stock

August 8, 2026 | insidertrades.com

Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 5,000 Shares

August 7, 2026 | marketbeat.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

August 7, 2026 | globenewswire.com

FY2029 EPS Estimates for Disc Medicine Lowered by Analyst

August 7, 2026 | marketbeat.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

August 6, 2026 | prnewswire.com

HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

August 6, 2026 | marketbeat.com

Dimensional Fund Advisors LP Raises Holdings in Disc Medicine, Inc. $IRON

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRCL, IRON, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$26.75 +0.24 (+0.91%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$26.85 +0.10 (+0.37%)

As of 08/14/2026 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Immunome NASDAQ:IMNM

$27.20 +0.78 (+2.95%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$27.04 -0.15 (-0.57%)

As of 08/14/2026 07:34 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Disc Medicine NASDAQ:IRON

$78.84 -1.17 (-1.46%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$79.00 +0.16 (+0.20%)

As of 08/14/2026 07:34 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCL, IRON, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCL, IRON, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCL, IRON, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRCL, IRON, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Gracell Biotechnologies NASDAQ:GRCL

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCL, IRON, IMNM, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCL, IRON, IMNM, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCL, IRON, IMNM, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRCL, IRON, IMNM, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Gracell Biotechnologies NASDAQ:GRCL

Immunome NASDAQ:IMNM

Disc Medicine NASDAQ:IRON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools